Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Antidepressants trigger opposite reactions in different groups of serotonin-producing brain cells

A new study has uncovered how antidepressants affect different groups of serotonin-producing brain cells in opposite ways, offering new insights into why selective serotonin reuptake inhibitors (SSRIs) can cause unpleasant side effects at the start of treatment but lead to symptom relief over time.

8 Jun 2026

Antidepressant drugs detected at potentially harmful levels in waterways

Depression, anxiety and sleep disorders are among the conditions often treated with antidepressant drugs. Yet, up to 90% of these drugs pass through the body into wastewater.

3 Jun 2026

Ghrelin rises in depression despite obesity’s usual appetite-hormone suppression

Researchers found that both acylated and deacylated ghrelin were elevated in unmedicated adults with major depressive disorder and obesity compared with non-depressed adults with obesity. The cross-sectional findings suggest ghrelin-system dysregulation may be linked to depression in obesity, but larger longitudinal studies are needed to test whether ghrelin is a reliable biomarker.

27 May 2026

Special yoga intervention helps cancer survivors manage psychological side effects

University of Rochester Medicine is in the spotlight at a national meeting for a new discovery in integrative oncology: A special yoga intervention, the study shows, goes a step further than other side-effect therapies to improve four domains of physical and psychological side effects that most patients experience, including lifting mood and easing anxiety.

26 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University of Bristol-led pilot randomised controlled clinical trial, published in JAMA Psychiatry today [20 May].

20 May 2026

Psilocybin offers fast-acting alternative to traditional antidepressants

A single dose of the psychedelic substance psilocybin can provide rapid relief from depressive symptoms – within just a few days. This is shown by the first randomised, double-blind study in Sweden of psilocybin for depression. The effect persisted for over three months, according to researchers at Karolinska Institutet.

15 May 2026

Retinal stimulation via contact lenses effective as antidepressants in mice

Materials scientists have designed brain-stimulating contact lenses that are as effective as Prozac at treating depression in mice. The soft, transparent contact lenses have in-built electrodes that deliver mild electrical signals to the brain via the retina to stimulate specific brain regions associated with depression.

14 May 2026

Study links metabolic dysfunction to cognitive impairment in bipolar disorder

While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major depressive disorder are distinct.

11 May 2026

Study reveals how magnetic stimulation repairs depression-related brain circuits

Transcranial magnetic stimulation (TMS) is a non-invasive, FDA-approved therapy that uses brief magnetic pulses to treat depression, particularly in patients who do not respond to medication.

7 May 2026

Finding new ways to mimic ketamine’s antidepressant effects

Weill Cornell Medicine investigators have "reverse engineered" ketamine's antidepressant effects to identify potential new strategies for treating depression.

4 May 2026

Autism risk rises with multiple medications taken during pregnancy

A study links maternal use of cholesterol-inhibiting medications during pregnancy to increased autism risk in children, urging caution in prescribing practices.

22 Apr 2026

Brain organoids may guide Alzheimer’s diagnosis and treatment

Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients with Alzheimer's disease may be used to evaluate how certain patients with the neurodegenerative condition may respond to drugs commonly prescribed to treat psychiatric symptoms of the disorder.

20 Apr 2026

Serotonin may worsen tinnitus symptoms, mice study finds

The same neurotransmitter commonly leveraged to relieve symptoms of depression and anxiety also may exacerbate a vexing condition known as tinnitus, according to new research published in the Proceedings of the National Academy of Sciences.

20 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Higher mortality risk in IBS patients using antidepressants

Research indicates that antidepressant use in IBS is linked to a 35% higher risk of all-cause mortality, highlighting safety issues with long-term treatment.

13 Apr 2026

When omega-3 may help mental health and when they may not

Investigating omega-3 fatty acids, this review highlights their impact on mental health, inflammation, and the potential for therapeutic use in disorders.

10 Apr 2026

Long-term study links common IBS medications to mortality risk

A large, long-term study led by Cedars-Sinai Health Sciences University investigators suggests that some medications commonly prescribed to treat irritable bowel syndrome (IBS)-including antidepressants-may be associated with a small but measurable increase in the risk of death.

8 Apr 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

NOX-1 identified as key molecular target to prolong ketamine's antidepressant effects

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers rapid relief, its antidepressant effects fade within a few weeks.

30 Mar 2026